Discussions are underway in and outside the pharmaceutical industry to explore a new NHI price revision method for listed medicines that could replace the current rules based on market prices. Parties like the Study Group on Drug Pricing and Distribution…
REGULATORY
US, European Trade Groups Oppose Tighter Re-Pricing Rules
US and European pharma industry associations said on December 6 that they are fully aligned with their Japanese counterparts in their requests towards Japan's next drug pricing reform in April, expressing their positions against the proposed tightening of re-pricing rules…
To read the full story
Related Article
- Chuikyo Pushes Up-to-5-Band Plan to Address Unreasonable Generic Price Rises, Prods Industry Reorganization
December 9, 2019
- Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
December 9, 2019
- Industry Urges Careful Approach to Creating Special Rule for Indication Change Re-Pricing: Chuikyo
November 25, 2019
- Chuikyo Positive about Changing Rules to Set Sales Thresholds after Market Expansion Re-Pricing Applied
November 11, 2019
REGULATORY
- Enhertu, BMS’s Luspatercept Grab Orphan Designation
September 22, 2022
- Japan Healthcare Spending Logs 44.2 Trillion Yen in FY2021, Up 4.6% on Post-Pandemic Rebound
September 21, 2022
- LDP OKs Draft Bill to Amend Infectious Disease Act to Enable Requests for Vaccine Production Boost in Emergencies
September 21, 2022
- 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
- Japan Launches Omicron Booster Program for COVID-19
September 21, 2022
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…